KW-2449
|
|
|
ABL Inhibitor (pan)
8
Aurka Inhibitors
23
FGFR1 Inhibitor
21
FLT3 Inhibitor
48
|
KW-2449 is a multikinase inhibitor with activity against FLT3, FLT3 D385Y, ABL1, ABL1 T315I, FGFR1, and AURKA, which may inhibit cancer cell proliferation and tumor growth (PMID: 19541823). |
Debio 0617B
|
|
|
ABL Inhibitor (pan)
8
CSF1R Inhibitor
22
FLT3 Inhibitor
48
JAK Inhibitor (Pan)
8
KIT Inhibitor
48
PDGFR Inhibitor (Pan)
27
SRC Inhibitor
26
VEGFR Inhibitor (Pan)
29
|
Debio 0617B is a multi-kinase inhibitor of SRC, JAK, and ABL, the class III kinases, CSF1R, FLT3, KIT, and PDGFR, and the class V kinases, VEGFR 1/2/3, which may result in inhibition of Stat3 and Stat5 signaling, leading to inhibition of tumor cell growth and metastasis (PMID: 27439479). |
Dasatinib
|
Sprycel |
BMS-354825 |
ABL Inhibitor (pan)
8
BCR-ABL Inhibitor
23
BTK inhibitor
20
CSF1R Inhibitor
22
DDR1 Inhibitor
8
DDR2 inhibitor
7
KIT Inhibitor
48
PDGFR Inhibitor (Pan)
27
SRC Inhibitor
26
TNK2 Inhibitor
6
|
Sprycel (dasatinib) is an inhibitor of the SRC-family of protein kinases, BCR-ABL, and ABL, and has additional activity against other kinases including KIT, DDR1/2, PDGFRA/B, and EPHA2, which prevents cell growth (PMID: 25709401, PMID: 25284748, PMID: 18797457). Sprycel (dasatinib) is FDA approved for both Philadelphia chromosome positive adult and pediatric chronic myelogenous leukemia and adult acute lymphoblastic leukemia (FDA.gov). |
Nilotinib
|
Tasigna |
AMN-107 |
ABL Inhibitor (pan)
8
BCR-ABL Inhibitor
23
CSF1R Inhibitor
22
DDR1 Inhibitor
8
DDR2 inhibitor
7
KIT Inhibitor
48
PDGFR Inhibitor (Pan)
27
|
Tasigna (nilotinib) inhibits several tyrosine kinases including BCR-ABL, PDGFR, KIT, DDR and CSF-1R, potentially resulting in reduced tumor cell proliferation (PMID: 21419934, PMID: 25284748). Tasigna (nilotinib) is FDA approved for use in patients with Ph+ chronic myeloid leukemia (FDA.gov). |
Bosutinib
|
Bosulif |
SKI-606 |
ABL Inhibitor (pan)
8
AXL Inhibitor
24
BTK inhibitor
20
SRC Inhibitor
26
TNK2 Inhibitor
6
|
Bosulif (bosutinib) inhibits SRC and ABL kinases, and has additional activity against other kinases including AXL, TNK2, BTK, resulting in decreased pathway activation and inhibition of tumor cell proliferation (PMID: 12543790, PMID: 19039322, PMID: 26555154). Bosulif (bosutinib) is FDA approved for use in patients with Ph+ (BCR-ABL) chronic myelogenous leukemia (FDA.gov). |
PP-121
|
|
|
ABL Inhibitor (pan)
8
mTOR Inhibitor
48
PDGFR Inhibitor (Pan)
27
SRC Inhibitor
26
VEGFR2 Inhibitor
34
|
PP-121 inhibits several types of kinases including, PDGFR, Hck, mTOR, KDR (VEGFR2), Src and Abl to prevent cell proliferation (PMID: 24867098). |
RXDX-105
|
|
AC013773|CEP-32496 |
ABL Inhibitor (pan)
8
ABL1 Inhibitor
4
BCR-ABL Inhibitor
23
BRAF Inhibitor
18
CRAF Inhibitor
10
KIT Inhibitor
48
PDGFR-beta Inhibitor
13
RET Inhibitor
36
VEGFR2 Inhibitor
34
|
RXDX-105 (CEP-32496) inhibits wild-type BRAF, BRAF V600E, c-RAF, ABL1 (and BCR-ABL), c-KIT, RET, PDGFR beta, and VEGFR2, potentially resulting in decreased tumor growth (PMID: 22319199). |
Imatinib mesylate
|
Gleevec |
CGP-57148B|STI571 |
ABL Inhibitor (pan)
8
BCR-ABL Inhibitor
23
CSF1R Inhibitor
22
KIT Inhibitor
48
PDGFR Inhibitor (Pan)
27
|
Gleevec (imatinib mesylate) is a multi-target inhibitor of c-Kit, Pdgfr, and Bcr-Abl (NCI Drug Dictionary). Gleevec (imatinib mesylate) is FDA approved for c-KIT positive GIST and dermatofibrosarcoma protuberans, Philadelphia chromosome positive chronic
myeloid leukemia, and FIP1L1-PDGFRA positive chronic eosinophilic leukemia (FDA.gov). |